Clinical trials: Hereditary Hemorrhagic Telangiectasia
Telangiectasia, Hereditary Hemorrhagic
Studies of White Blood Cells Derived From HHT Patients
Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an inherited vascular disease that leads to the development of dilated and fragile blood vessels.
- Trial name
- NCT00230633
- Where
- United Kingdom
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Hereditary Haemorrhagic Telangiectasia
Immunological Effects of Iron Supplementation in HHT Disease
Hereditary haemorrhagic telangiectasia (HHT), is a rare genetic vascular disorder with autosomal dominant inheritance. Its prevalence is estimated at approximately 1 in 6,000 individuals in France.
- Trial name
- Fer&RO (NCT07111598)
- Testing
- Blood test at D0, Blood test at D+3 months
- Where
- France
- Volunteers
- 155 people
- Sponsor
- Hospices Civils de Lyon
HHT, Hereditary Hemorrhagic Telangiectasia
Intranasal Bevacizumab for HHT-Related Epistaxis
This is a randomized, controlled, double-blind, placebo-controlled trial of intranasal Avastin (bevacizumab) injection versus saline control for control of HHT-related epistaxis when used in conjunction with bipolar…
- Conditions
- HHT, Hereditary Hemorrhagic Telangiectasia, Epistaxis, Nose Bleeds
- Trial name
- NCT02389959
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
Telangiectasia, Hereditary Hemorrhagic, Rendu Osler Disease
Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.
The recognized manifestations of HHT are all due to abnormalities in vascular structure. Epistaxis are spontaneous, very variable, may occur as often as several times every day, and are recurrent in 90% of patients and associated…
- Trial name
- EPICURE (NCT03954782)
- Testing
- Nintedanib 150 mg and 100 mg soft capsules
- Where
- 8 sites in France
- Volunteers
- 61 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia (HHT)
Assess Safety and Efficacy of VAD044 in HHT Patients
Part I: The purpose of this Phase 1b proof of concept study, randomised, placebo controlled, double blind, multicentre study is to asssess safety and efficacy of 2 doses of VAD044 in adult HHT patients.
- Trial name
- NCT05406362
- Testing
- VAD044 Part I, VAD044 Part II
- Where
- 7 sites in United States, Belgium and 4 more
- Volunteers
- 75 people
- Sponsor
- Vaderis Therapeutics AG
Epistaxis
NOrth American Study for the Treatment of Recurrent epIstaxis With DoxycycLine: The NOSTRIL Trial
The purpose of this research study is to determine whether Doxycycline can be used to control nosebleeds (epistaxis) for patients with Hereditary Hemorrhagic Telangiectasia (HHT).
- Trial name
- NOSTRIL (NCT04167085)
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, Los Angeles
Hereditary Haemorrhagic Telangiectasia
Genotype Expression and Phenotype of Endothelial Cells, Carrying an ACVRL1, ENG or SMAD4 Mutation, in Response to BMP9 for the Identification of New Therapeutic Targets in Hereditary Haemorrhagic Telangiectasia
Hereditary hemorrhagic telangiectasia (HHT) or Osler-Weber-Rendu syndrome patients are carriers of a heterozygous mutation of the activin receptor-like kinase 1 (ACVRL1), Endoglin (ENG) or Mothers against decapentaplegic homolog…
- Trial name
- CAERO (NCT05632484)
- Testing
- Cord blood sampling, Cord sampling
- Where
- 3 sites in France
- Volunteers
- 16 people
- Sponsor
- Hospices Civils de Lyon
Cancer
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Antifungals, such as caspofungin acetate, may be effective in treating fungal infections caused by chemotherapy or stem cell transplant.
- Trial name
- NCT00110045
- Testing
- caspofungin acetate
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Hereditary Hemorrhagic Telangiectasia (HHT), Rendu Osler Disease
IV Bevacizumab Treatment of Patients With Hereditary Hemorrhagic Telangiectasia (HHT) or Rendu-Osler (RO) Disease: A Retrospective Analysis of French Cohort Data From 2009 to 2024
Rendu-Osler disease (RO), also known as Hereditary Haemorrhagic Telangiectasia (HHT), is an autosomal dominant genetic disorder. Its pathophysiology is associated with an imbalance in angiogenic balance.
- Trial name
- CoBé (NCT07772050)
- Testing
- Real World data study.
- Where
- France
- Volunteers
- 244 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia, Epistaxis Nosebleed
Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)
This study will investigate the effectiveness of oral low-dose tacrolimus for the treatment of recurrent nasal hemorrhage in HHT subjects.
- Trial name
- NCT04646356
- Testing
- Tacrolimus capsule (low-dose)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Unity Health Toronto
Hereditary Hemorrhagic Telangiectasia (HHT), Nosebleeds
Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
This study is for patients with recurrent epistaxis (nosebleeds) as a result of Hereditary Hemorrhagic Telangiectasia (HHT). The aim is to determine if ranibizumab, topically applied will diminish epistaxis in patients with HHT…
- Trial name
- NCT01406639
- Testing
- Ranibizumab
- Sponsor
- University of California, San Diego
Hereditary Haemorrhagic Telangiectasia (HHT)
Immunmodulation in Patients With HHT
Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an inherited multisystemic disorder. Literature suggests that HHT is often associated with higher frequency of infectious diseases.
- Trial name
- NCT02983253
- Testing
- blood sample
- Where
- Germany
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- University Hospital, Essen
Hereditary Hemorrhagic Telangiectasia (HHT)
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study
This is a multicenter U.S. longitudinal study evaluating patients with hereditary hemorrhagic telangiectasia who participated in the PATH-HHT clinical trial of pomalidomide for the treatment of HHT.
- Trial name
- PATH-HHT ATLAS (NCT07018401)
- Testing
- Pomalidomide
- Where
- 11 sites in United States
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital
Hereditary Hemorrhagic Telangiectasia
Development of a Quality of Life Measurement Scale in Hereditary Haemorrhagic Telangiectasia (HHT) Disease.
Hereditary Haemorrhagic Telangiectasia (HHT) is a rare inherited genetic disease of autosomal dominant inheritance with a prevalence of 1/6000.
- Trial name
- ELECT-RO (NCT03695874)
- Testing
- Phase 1 : fill out 1 scale, Phase 2 : fill out 1 scale and 4 questionnaires
- Where
- France
- Volunteers
- 643 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia, Epistaxis
Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT
Compare the frequency of epistaxis and quality of life related to nasal bleeding in patients with HHT colonized with sataphylococo before and after being treated with mupirocin ointment.
- Trial name
- NCT02963129
- Testing
- Mupirocin
- Where
- 2 sites in Argentina
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires
Osler-Rendu-Weber Disease, Osler-Rendu Disease
Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia
This study will explore the factors that influence screening behaviors of adults diagnosed with hereditary hemorrhagic telangiectasia (HHT), an inherited condition in which blood vessel defects called arteriovenous malformations…
- Conditions
- Osler-Rendu-Weber Disease, Osler-Rendu Disease, Telangiectasia, Hereditary Hemorrhagic
- Trial name
- NCT00684879
- Where
- United States
- Volunteers
- 320 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Hereditary Hemorrhagic Telangiectasia, Osler Weber Rendu Disease
Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients
Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder of angiogenesis associated with disabling epistaxis. Management of these nose bleedings requires more effective treatment.
- Trial name
- EPERO (NCT04113187)
- Testing
- Propranolol treatment
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Bordeaux
Hereditary Hemorrhagic Telangiectasia, Epistaxis
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
During the Efficacy Study (Part B), the investigators will study whether Pazopanib, taken daily for 24 weeks, will reduce the severity of nose bleeds in patients with hereditary hemorrhagic telangiectasia (HHT).
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia, Nosebleed
- Trial name
- Paz (NCT03850964)
- Testing
- Pazopanib
- Where
- 11 sites in United States
- Volunteers
- 71 people
- Sponsor
- Cure HHT
Hereditary Hemorrhagic Telangiectasia, Gastrointestinal Hemorrhage
Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber
The purpose of this study is to determine whether long-acting octreotide is safe and effective in the treatment of patients with Rendu-Osler-Weber (e.g. HHT).
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Gastrointestinal Hemorrhage, Anemia
- Trial name
- ROW (NCT02874326)
- Testing
- Octreotide LAR
- Where
- 2 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Radboud University Medical Center
Hemorrhagic Hereditary Telangiectasia, HHT
Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH
Bevacizumab is widely prescribed for the treatment of severe bleeding related to epistaxis or gastrointestinal bleeding in HHT. We studied the efficacy of bevacizumab on severe bleeding in HHT patients in a randomized study…
- Trial name
- BEST (NCT06039124)
- Testing
- bevacizumab treatment
- Where
- 3 sites in France
- Volunteers
- 23 people
- Sponsor
- Hospices Civils de Lyon